Navigation Links
Evidence supports blocking immune response to enhance viral therapy against solid tumors
Date:3/13/2013

Following several years of study, investigators have found more evidence that viral therapy to treat solid tumors can be enhanced by blocking the body's natural immune response.

Oncolytic viruses have shown promise as anticancer agents, with variations of the herpes simplex virus (HSV) among the most commonly used. However, many studies have shown that the effectiveness of viral therapy to eradicate tumors has not been as successful with patients as it has been in the lab. These results have led researchers to examine the body's immune system response to determine what effect it may have toward decreasing the effectiveness of viral therapy.

A new study, published in the March 12, 2013 issue of Molecular Therapy and led by Timothy Cripe, MD, PhD, division chief of Hematology/Oncology and Bone Marrow Transplantation at Nationwide Children's Hospital, is shedding additional light on how viral therapy combined with a suppressed immune response could be more effective against solid tumors.

Dr. Cripe and a team of investigators studied the effects of vascular endothelial growth factor (VEGF), a substance commonly released during an immune, or pro-inflammatory, response to a viral infection. VEGF is responsible for angiogenesis, new blood vessel growth near an injured or infected site.

VEGF is also important for tumor growth, raising the possibility that its response to virus infection might get in the way of viral therapy.

"We sought to determine if a pro-angiogenic response occurs during viral therapy for cancer, to what extent it may limit antitumor effectiveness, and if it could be counteracted by antiangiogenic therapy," explains Dr. Cripe, who is also a professor of Pediatrics at The Ohio State University College of Medicine.

Their research demonstrates that an anti-VEGF antibody markedly enhances the anti-tumor effect of an oncolytic virus (oHSV) injected into a tumor. They also discovered that the anti-tumor effect was due to both enhanced antiangiogenesis and the modulation of the tumor's immune response. However the effect was not due to the virus replicating within the tumor.

"One of the most important outcomes of this study is the strong rationale for developing a clinical trial combining the use of oHSV and the FDA-approved anti-VEGF product, bevacizumab," said Dr. Cripe. "Virus therapy or anti-VEGF therapy alone each independently prolonged survival of mouse models implanted with Ewing sarcoma, but all of those mice eventually succumbed to their cancer. In contrast, the combination of virus and anti-VEGF therapies cured 90 percent of the mice. Virus therapy is a very promising area of cancer treatment, and studies such as these will bring us even closer to success."

Future studies will be developed to determine if immune responses vary among tumor types and if targeted therapy for specific aspects of the immune response will be more effective than completely suppressing the immune system.


'/>"/>

Contact: Mary Ellen Peacock
maryellen.peacock@nationwidechildrens.org
614-355-0492
Nationwide Children's Hospital
Source:Eurekalert

Related medicine news :

1. More Evidence Whooping Cough Protection Wanes
2. First evidence that obesity gene is risk factor for melanoma
3. More Evidence That Smoking Raises Breast Cancer Risk
4. Evidence shows concussions require long-term follow-up for players
5. Review: Few effective, evidence-based interventions for children exposed to traumatic events
6. Reassuring evidence: Anticancer drug does not accelerate tumor growth after treatment ends
7. JSCM publishes issue on NIDRR-funded project on practice-based evidence in SCI rehabilitation
8. Review Finds No Evidence Alzheimers, Parkinsons Are Infectious
9. No Evidence That Lupus Drugs Lead to Cancer, Says Study
10. More Evidence Ties Heart Disease to Mental Decline
11. Patient expectations of acute bronchitis not consistent with the best evidence
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... ... ... Cheryl Bowker of Bowker Insurance Group has been presented with one of ... McKenna ran one of Allstate’s most successful agencies for 48 years, but it was ... The award named for him is not given every year, but only when an ...
(Date:5/25/2016)... ... May 25, 2016 , ... Casa Velas, an adults-only ... of precious stones to complement its new wellness suites . The two 1,350 ... feature a plethora of special services and insuite amenities, from a custom soap selection ...
(Date:5/25/2016)... ... May 25, 2016 , ... Laser Skin & ... turn back the hands of time of female aging. The Juliet™ ... Women with symptoms such as leakage, laxity, itchiness and pain have reported real relief ...
(Date:5/25/2016)... ... 25, 2016 , ... First Choice Emergency Room , the largest network ... as the Medical Director of its new DeSoto facility. , “We are pleased ... location,” said Dr. James M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. ...
(Date:5/24/2016)... ... May 24, 2016 , ... Sterling Global Products is ... unique and patented refillable hanging wipe dispenser. The campaign kick-off video is located via ... end June 25, 2016. The goal is to raise $1,000 per day for a ...
Breaking Medicine News(10 mins):
(Date:5/23/2016)... May 23, 2016 Transparency Market ... Exocrine Pancreatic Insufficiency Market - Global Industry Analysis, Size, ... According to the report, the exocrine pancreatic insufficiency market ... from 2015 to 2023 to reach US$2.85 Bn by ... condition characterized by the deficiency of the exocrine pancreatic ...
(Date:5/23/2016)... May 23, 2016 Clarifying Vision ... and Monitoring, and Vision Care What can ... are going to grow at the fastest rates? This ... 2026, assessing data, trends, opportunities and prospects. ... graphs. Discover the most lucrative areas in the industry ...
(Date:5/23/2016)... Non-invasive diagnostic test realizes the ... ,Technology to be presented at Yissum’s booth, at IATI-BIOMED ... Company of the Hebrew University of Jerusalem announced ... Aurum Ventures MKI, the technology investment arm of Morris ... approach for early detection of multiple diseases by analyzing ...
Breaking Medicine Technology: